• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

“”：直接口服抗凝剂时代的心房颤动和人工瓣膜患者的抗凝管理。

"": Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants.

机构信息

Department of Cardiology, AORN Ospedali dei Colli-Monaldi Hospital, 80131 Naples, Italy.

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.

出版信息

Medicina (Kaunas). 2019 Aug 4;55(8):437. doi: 10.3390/medicina55080437.

DOI:10.3390/medicina55080437
PMID:31382702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6722984/
Abstract

Valvular heart disease and atrial fibrillation often coexist. Oral vitamin K antagonists have represented the main anticoagulation management for antithrombotic prevention in this setting for decades. Novel direct oral anticoagulants (DOACs) are a new class of drugs and currently, due to their well-established efficacy and security, they represent the main therapeutic option in non-valvular atrial fibrillation. Some new evidences are exploring the role of DOACs in patients with valvular atrial fibrillation (mechanical and biological prosthetic valves). In this review we explore the data available in the medical literature to establish the actual role of DOACs in patients with valvular heart disease and atrial fibrillation.

摘要

瓣膜性心脏病和心房颤动常常并存。几十年来，口服维生素 K 拮抗剂一直是这种情况下抗血栓预防的主要抗凝管理方法。新型直接口服抗凝剂（DOACs）是一类新药，目前由于其疗效和安全性已得到充分证实，是治疗非瓣膜性心房颤动的主要选择。一些新的证据正在探索 DOAC 在瓣膜性心房颤动（机械和生物假体瓣膜）患者中的作用。在这篇综述中，我们探讨了医学文献中可用的数据，以确定 DOAC 在瓣膜性心脏病和心房颤动患者中的实际作用。

相似文献

1
"": Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants.“”：直接口服抗凝剂时代的心房颤动和人工瓣膜患者的抗凝管理。
Medicina (Kaunas). 2019 Aug 4;55(8):437. doi: 10.3390/medicina55080437.
2
Use of oral anticoagulants in complex clinical situations with atrial fibrillation.在伴有房颤的复杂临床情况下使用口服抗凝药物。
Med Clin (Barc). 2018 Jun;150 Suppl 1:8-24. doi: 10.1016/S0025-7753(18)30666-3.
3
Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?直接口服抗凝剂可否用于预防瓣膜性心房颤动患者的卒中？
Curr Cardiol Rep. 2019 Aug 31;21(10):118. doi: 10.1007/s11886-019-1199-4.
4
Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves: A Meta-Analysis.除重度二尖瓣狭窄和机械瓣膜外的心房颤动合并瓣膜性心脏病患者使用直接口服抗凝剂的荟萃分析。
Circulation. 2017 Feb 14;135(7):714-716. doi: 10.1161/CIRCULATIONAHA.116.026793.
5
Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.心房颤动合并心脏瓣膜异常患者的卒中预防策略：对“瓣膜性”心房颤动的认知：欧洲心律协会调查结果
Europace. 2016 Oct;18(10):1593-1598. doi: 10.1093/europace/euw302.
6
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).心房颤动合并心脏瓣膜病的抗栓治疗：欧洲心律协会（EHRA）和欧洲心脏病学会血栓工作组的联合共识文件，得到 ESC 心脏瓣膜病工作组、南非心脏协会（SA Heart）、心律学会（HRS）、亚太心律学会（APHRS）、南非心脏协会（SA Heart）和拉丁美洲心脏刺激和电生理学会（SOLEACE）的认可。
Europace. 2017 Nov 1;19(11):1757-1758. doi: 10.1093/europace/eux240.
7
Unresolved issues in the use of direct acting oral anticoagulants.直接作用口服抗凝剂使用中的未解决问题。
Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(12):913-921. doi: 10.1080/14779072.2023.2271388. Epub 2023 Dec 13.
8
[Stroke prevention with direct oral anticoagulants in patients with non-valvular atrial fibrillation].非瓣膜性心房颤动患者使用直接口服抗凝剂预防卒中
Dtsch Med Wochenschr. 2015 May;140(10):750-5. doi: 10.1055/s-0041-102000. Epub 2015 May 13.
9
Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.非维生素K口服抗凝剂用于特殊人群房颤患者的卒中预防
Adv Ther. 2017 Jun;34(6):1283-1290. doi: 10.1007/s12325-017-0550-7. Epub 2017 May 10.
10
Direct-acting oral anticoagulants in patients with atrial fibrillation and valvular heart disease.直接口服抗凝剂在心房颤动和心脏瓣膜病患者中的应用。
JAAPA. 2022 Sep 1;35(9):17-18. doi: 10.1097/01.JAA.0000854516.90788.a8.

引用本文的文献

1
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Mechanical Heart Valves: A Systematic Review.直接口服抗凝剂与华法林在机械心脏瓣膜患者中的有效性和安全性：一项系统评价。
Cureus. 2025 Aug 10;17(8):e89736. doi: 10.7759/cureus.89736. eCollection 2025 Aug.
2
Long-Term Outcomes of Mechanical Versus Bioprosthetic Aortic Valve Replacement: A Systematic Review and Meta-Analysis.机械瓣与生物瓣主动脉瓣置换术的长期结局：一项系统评价和荟萃分析
Cureus. 2024 Jan 19;16(1):e52550. doi: 10.7759/cureus.52550. eCollection 2024 Jan.
3
Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials.来源于实践的数据用于非维生素K拮抗剂口服抗凝治疗，以补充随机试验的观察结果。
Eur Heart J Suppl. 2020 Sep 15;22(Suppl I):I1-I12. doi: 10.1093/eurheartj/suaa100. eCollection 2020 Sep.

本文引用的文献

1
Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.阿哌沙班对比华法林在伴有既往生物瓣置换或修复的心房颤动患者中的疗效和安全性：来自 ARISTOTLE 试验的结果。
Clin Cardiol. 2019 May;42(5):568-571. doi: 10.1002/clc.23178. Epub 2019 Apr 9.
2
Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.达比加群酯与维生素 K 拮抗剂治疗心房颤动患者三联抗栓治疗的安全性和有效性：一项初步研究。
Biomed Res Int. 2019 Feb 13;2019:5473240. doi: 10.1155/2019/5473240. eCollection 2019.
3
Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late.直接口服抗凝剂在 80 岁以上的房颤患者中的应用：永远不会太晚。
J Cardiovasc Pharmacol. 2019 Apr;73(4):207-214. doi: 10.1097/FJC.0000000000000661.
4
Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study.在心房颤动患者中持续使用阿哌沙班：一项回顾性多中心研究。
J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):66-73. doi: 10.2459/JCM.0000000000000744.
5
Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study.利伐沙班与华法林在机械心脏瓣膜患者中的比较：RIWA 研究的原理和设计。
Drugs R D. 2018 Dec;18(4):303-308. doi: 10.1007/s40268-018-0249-5.
6
Atrial Fibrillation and Malignancy: The Clinical Performance of Non-Vitamin K Oral Anticoagulants-A Systematic Review.心房颤动与恶性肿瘤：非维生素 K 口服抗凝剂的临床表现——系统评价。
Semin Thromb Hemost. 2019 Mar;45(2):205-214. doi: 10.1055/s-0038-1661386. Epub 2018 Aug 17.
7
Usefulness and Safety of Rivaroxaban in Patients Following Isolated Mitral Valve Replacement With a Mechanical Prosthesis.利伐沙班在接受机械二尖瓣置换术的孤立性二尖瓣置换术后患者中的应用的有效性和安全性。
Am J Cardiol. 2018 Sep 15;122(6):1047-1050. doi: 10.1016/j.amjcard.2018.06.015. Epub 2018 Aug 8.
8
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).2018 年欧洲共识文件：急性冠状动脉综合征和/或经皮心血管介入治疗的心房颤动患者抗栓治疗管理：欧洲心律协会（EHRA）、欧洲心脏病学会血栓工作组、欧洲经皮心血管介入协会（EAPCI）和欧洲急性心脏护理协会（ACCA）的联合共识文件，得到了心律学会（HRS）、亚太心律学会（APHRS）、拉丁美洲心律学会（LAHRS）和南非心脏心律失常学会（CASSA）的认可。
Europace. 2019 Feb 1;21(2):192-193. doi: 10.1093/europace/euy174.
9
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.2018 年欧洲心脏病学会实用指南：非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中的应用：执行摘要。
Europace. 2018 Aug 1;20(8):1231-1242. doi: 10.1093/europace/euy054.
10
Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience.非维生素 K 拮抗剂口服抗凝剂在心房颤动和生物瓣心脏瓣膜/既往手术瓣膜修复患者中的应用：一项多中心临床实践经验。
Semin Thromb Hemost. 2018 Jun;44(4):364-369. doi: 10.1055/s-0037-1615261. Epub 2018 Jan 5.